# Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

> **NCT04621188** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 54 (actual)

## Conditions studied

- Non Small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT04621188
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-19
- **Primary completion:** 2025-02-26
- **Final completion:** 2027-02
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04621188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04621188, "Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04621188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*